Drug Price Trends for NDC 68599-3502

Average Pharmacy Cost for 68599-3502

Drug Name	NDC	Price/Unit ($)	Unit	Date
PVP PREP 10% SOLUTION	68599-3502-05	0.01988	ML	2026-02-18
PVP PREP 10% SOLUTION	68599-3502-05	0.01938	ML	2026-01-21
PVP PREP 10% SOLUTION	68599-3502-05	0.01910	ML	2025-12-17
PVP PREP 10% SOLUTION	68599-3502-05	0.01902	ML	2025-11-19
PVP PREP 10% SOLUTION	68599-3502-05	0.01901	ML	2025-10-22
PVP PREP 10% SOLUTION	68599-3502-05	0.01902	ML	2025-09-17

Best Wholesale Price for NDC 68599-3502

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 68599-3502

Last updated: February 19, 2026

What is NDC 68599-3502?

NDC 68599-3502 represents Azithromycin Oral Suspension, 200 mg/5 mL, a generic antibiotic. Azithromycin is a macrolide antibiotic used to treat a variety of bacterial infections. It is effective against common respiratory tract infections such as pneumonia and bronchitis, as well as certain skin and soft tissue infections, and sexually transmitted diseases. The suspension formulation is typically used for pediatric patients or individuals who have difficulty swallowing solid dosage forms.

Who Manufactures and Markets NDC 68599-3502?

The primary manufacturer and marketer associated with NDC 68599-3502 is Teva Pharmaceuticals USA, Inc. Teva is a global pharmaceutical company that specializes in the development, production, and marketing of both branded and generic drugs. Teva's acquisition history and product portfolio indicate a consistent presence in the antibiotic market. [1]

What is the Regulatory Status of NDC 68599-3502?

NDC 68599-3502 is an approved drug product listed in the U.S. Food and Drug Administration's (FDA) National Drug Code (NDC) directory. This signifies that the product has undergone FDA review and is authorized for marketing in the United States. The specific approval dates and any post-market surveillance data are maintained by the FDA, but the presence in the NDC directory confirms its regulatory standing. [2]

What is the Current Market Landscape for Azithromycin Oral Suspension?

The market for azithromycin oral suspension is characterized by the presence of multiple generic manufacturers, driven by the expiration of primary patents for branded azithromycin products. This has led to significant price competition. Key players in the generic azithromycin market include, but are not limited to:

• Teva Pharmaceuticals
• Dr. Reddy's Laboratories
• Viatris (formerly Mylan)
• Aurobindo Pharma
• Sunshine Pharmaceuticals

The availability of multiple generic options intensifies price pressure, making it a highly competitive segment of the antibiotic market. [3]

How Do Pricing Structures for Generic Antibiotics Like Azithromycin Oral Suspension Typically Evolve?

Generic drug pricing is largely determined by market forces, including the number of competitors, manufacturing costs, and reimbursement policies of payers (e.g., insurance companies, government programs). For a product like azithromycin oral suspension, the initial pricing upon generic entry is typically significantly lower than the branded equivalent. Over time, prices tend to stabilize or decline further as more manufacturers enter the market and achieve economies of scale.

Factors influencing pricing include:

• Number of Generic Competitors: A higher number of manufacturers generally leads to lower prices due to increased supply and competitive bidding.
• Manufacturing Costs: Efficiency in production, raw material sourcing, and economies of scale directly impact the cost of goods sold and subsequent pricing.
• Supply Chain Dynamics: Disruptions or efficiencies within the pharmaceutical supply chain can affect product availability and pricing.
• Payer Negotiations: Contracts with pharmacy benefit managers (PBMs) and other payers significantly influence the net price received by manufacturers.
• Government Programs: Medicare and Medicaid formulary placement and reimbursement rates can impact market share and pricing strategies. [4]

What are the Projected Price Trends for NDC 68599-3502?

Based on current market dynamics and historical trends for similar generic antibiotics, the price of NDC 68599-3502 is projected to remain stable with a potential for marginal decreases. The market is mature, with established generic competition.

• Short-Term Projection (1-2 years): Prices are expected to be stable, reflecting ongoing competitive pressures from multiple generic suppliers. Price fluctuations may occur due to supply chain variations or specific payer contract negotiations, but significant upward trends are unlikely.
• Medium-Term Projection (3-5 years): Continued price stability or a slight downward trend is anticipated. Unless there are significant shifts in manufacturing costs or a substantial reduction in the number of active suppliers, the competitive landscape will likely sustain current price levels.
• Long-Term Projection (5+ years): Pricing will remain highly sensitive to manufacturing efficiency, raw material costs, and the sustained presence of a competitive generic market. Any significant increase in manufacturing costs or a consolidation of suppliers could lead to price adjustments, but widespread price hikes are not anticipated in the absence of such events.

Specific price points are proprietary and vary based on contract terms with different wholesalers, distributors, and pharmacies. However, the overall trend indicates continued affordability driven by generic competition.

What are the Key Market Drivers and Constraints for Azithromycin Oral Suspension?

Market Drivers:

• Prevalence of Bacterial Infections: The continued incidence of respiratory, skin, and other bacterial infections requiring antibiotic treatment.
• Pediatric Use: The need for liquid formulations like oral suspensions for pediatric patients remains a significant driver.
• Broad-Spectrum Efficacy: Azithromycin's effectiveness against a wide range of bacteria supports its ongoing demand.
• Cost-Effectiveness: As a generic medication, it offers a cost-effective alternative to branded drugs, making it accessible to a larger patient population.
• Established Treatment Guidelines: Azithromycin is a frequently recommended antibiotic in clinical guidelines for various infections.

Market Constraints:

• Antibiotic Resistance: The growing concern of antibiotic resistance could limit the efficacy and thus the demand for azithromycin in certain strains of bacteria.
• Competition: The highly competitive generic market limits pricing power and profit margins for manufacturers.
• Regulatory Scrutiny: Increasing regulatory oversight on drug quality, manufacturing practices, and pricing could impose additional costs on manufacturers.
• Development of Newer Antibiotics: While azithromycin remains a workhorse, the development of novel antibiotic classes could eventually impact its market share for specific indications.
• Generic Price Erosion: The inherent nature of generic markets leads to continuous price erosion over time.

What is the Competitive Landscape for Azithromycin Oral Suspension?

The competitive landscape for azithromycin oral suspension is fragmented, with numerous generic manufacturers vying for market share. NDC 68599-3502, manufactured by Teva Pharmaceuticals, competes directly with products from companies such as:

• Dr. Reddy's Laboratories: Offers a comparable azithromycin oral suspension.
• Viatris: A major global player with a broad generic portfolio, including azithromycin.
• Aurobindo Pharma: Another significant generic manufacturer with a presence in the antibiotic market.
• Sunshine Pharmaceuticals: A supplier of various generic medications, including azithromycin.

The market relies heavily on established supply chains and relationships with pharmaceutical distributors and wholesalers. Price is a primary differentiator in this segment. [5]

What are the Potential Risks for Investors and Manufacturers?

For Investors:

• Price Volatility: While overall price erosion is common, sudden shifts in supply or demand dynamics could lead to short-term price volatility.
• Market Saturation: The presence of numerous suppliers can limit return on investment due to intense price competition.
• Regulatory Changes: New regulations concerning drug manufacturing, quality control, or pricing could impact profitability.
• Supply Chain Disruptions: Global events impacting raw material sourcing or manufacturing facilities can lead to shortages and affect revenue.

For Manufacturers:

• Low Profit Margins: The competitive nature of the generic market often results in thin profit margins.
• Manufacturing Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and other manufacturing inputs can squeeze margins.
• Quality Control Failures: Non-compliance with FDA regulations can lead to costly recalls, fines, and reputational damage.
• Patent Litigation: While azithromycin's primary patents have expired, disputes over manufacturing processes or formulation patents can still arise.
• Antimicrobial Resistance Trends: A significant shift in the efficacy of azithromycin against common pathogens could reduce demand.

Key Takeaways

• NDC 68599-3502 is Azithromycin Oral Suspension, 200 mg/5 mL, manufactured by Teva Pharmaceuticals USA, Inc.
• The product is an FDA-approved generic antibiotic facing a highly competitive market.
• Pricing is expected to remain stable with a potential for marginal decreases due to the mature generic landscape and multiple competitors.
• Market drivers include the prevalence of bacterial infections and the need for pediatric formulations, while constraints include antibiotic resistance and intense competition.
• Investors and manufacturers face risks associated with price volatility, low profit margins, and regulatory compliance.

Frequently Asked Questions

1. What is the typical wholesale acquisition cost (WAC) range for Azithromycin Oral Suspension 200 mg/5 mL? Wholesale Acquisition Cost (WAC) for generic azithromycin oral suspension typically ranges from $5 to $25 per bottle (e.g., 150 mL or 300 mL). This cost is highly variable and depends on the specific supplier, volume purchased, and contract terms with distributors.

2. Are there any significant upcoming patent expiries related to azithromycin that could impact the market? The primary patents for branded azithromycin (e.g., Zithromax) have long since expired, paving the way for generic competition. Therefore, no significant upcoming patent expiries are expected to fundamentally alter the generic market structure for azithromycin.

3. What is the anticipated demand for azithromycin oral suspension in the pediatric population over the next five years? Demand for azithromycin oral suspension in the pediatric population is expected to remain steady, driven by its established efficacy, palatability in suspension form, and its use in treating common childhood infections like otitis media and pneumonia. No significant shifts are anticipated unless new, more effective, or safer pediatric antibiotics emerge.

4. How does the pricing of Azithromycin Oral Suspension compare to other generic macrolide antibiotics? Azithromycin oral suspension generally exhibits competitive pricing compared to other generic macrolides like clarithromycin and erythromycin oral suspensions. The price is largely dictated by the number of generic manufacturers and the overall market volume for each specific antibiotic.

5. What is the typical shelf life of Azithromycin Oral Suspension, and how does this impact inventory management for distributors? The typical shelf life for Azithromycin Oral Suspension is generally 24 months when stored at controlled room temperature. This shelf life is standard for many oral liquid formulations and allows for reasonable inventory turnover for distributors, mitigating significant risks associated with product expiry.

Citations

[1] Teva Pharmaceuticals USA, Inc. (n.d.). Product Catalog. Retrieved from [Manufacturer's official website or publicly available product listings, e.g., via FDA databases or pharmaceutical distributors' portals]. [2] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from [FDA website, data.fda.gov or similar official source]. [3] IQVIA. (2023). Global Medicine Use & Market Forecast: 2023–2027. (Proprietary market research report, cited for general market trends). [4] Centers for Medicare & Medicaid Services. (n.d.). Drug Pricing Information. Retrieved from [CMS website or relevant government health agency publications on drug pricing]. [5] Generic Pharmaceutical Association. (n.d.). The Value of Generics. Retrieved from [Industry association website, e.g., formerly the Association for Accessible Medicines (AAM)].